Lifecore Biomedical, Inc.

NasdaqGS:LFCR Stock Report

Market Cap: US$265.3m

Lifecore Biomedical Management

Management criteria checks 1/4

Lifecore Biomedical's CEO is Paul Josephs, appointed in May 2024, has a tenure of 1.75 years. total yearly compensation is $1.12M, comprised of 49.3% salary and 50.7% bonuses, including company stock and options. directly owns 0.62% of the company’s shares, worth $1.65M. The average tenure of the management team and the board of directors is 1.4 years and 1.8 years respectively.

Key information

Paul Josephs

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage49.31%
CEO tenure1.8yrs
CEO ownership0.6%
Management average tenure1.4yrs
Board average tenure1.8yrs

Recent management updates

Recent updates

Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) Subdued P/S Might Signal An Opportunity

Jan 20
Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) Subdued P/S Might Signal An Opportunity

Lifecore Biomedical: Wins Should Blow Previous 'New Business' Estimates Out Of The Water

Jan 14

Lifecore Biomedical (NASDAQ:LFCR) Is Making Moderate Use Of Debt

Jul 18
Lifecore Biomedical (NASDAQ:LFCR) Is Making Moderate Use Of Debt

A Piece Of The Puzzle Missing From Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) Share Price

May 02
A Piece Of The Puzzle Missing From Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) Share Price

Lifecore Biomedical: We Are Not Playing To Make 5% Or 10% Here

Mar 03
User avatar

Over 50 New Opportunities Expected From Business Development Expansion

Expanding business development and operational capacity is expected to drive revenue growth by broadening the customer base and enhancing earning potential.

Lifecore Biomedical: An Interesting CDMO Pure Play

Dec 01

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Soars 36% But It's A Story Of Risk Vs Reward

Nov 26
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Soars 36% But It's A Story Of Risk Vs Reward

Lifecore Biomedical: Finally A 'Pure Play' CDMO Business

Nov 12

Lifecore Biomedical: No Sale Soon Amidst Leverage And Uncertainty

Jun 24

White Falcon Capital - Lifecore Biomedical: Potential For Rapid Growth In Earnings And FCF Surge

Apr 20

Would Lifecore Biomedical (NASDAQ:LFCR) Be Better Off With Less Debt?

Jun 30
Would Lifecore Biomedical (NASDAQ:LFCR) Be Better Off With Less Debt?

Landec Non-GAAP EPS of -$0.32, revenue of $43.35M

Oct 06

Landec receives Nasdaq's notification on delayed annual report filing

Sep 09

Laughing Water Capital - Landec Corp. : A High Quality CDMO

Jul 27

Landec (NASDAQ:LNDC) Takes On Some Risk With Its Use Of Debt

Jun 24
Landec (NASDAQ:LNDC) Takes On Some Risk With Its Use Of Debt

CEO Compensation Analysis

How has Paul Josephs's remuneration changed compared to Lifecore Biomedical's earnings?
DateTotal CompensationSalaryCompany Earnings
May 25 2025US$1mUS$550k

-US$44m

Feb 23 2025n/an/a

-US$49m

Nov 24 2024n/an/a

-US$17m

Aug 25 2024n/an/a

US$6m

May 26 2024US$10mUS$11k

US$9m

Compensation vs Market: Paul's total compensation ($USD1.12M) is about average for companies of similar size in the US market ($USD1.47M).

Compensation vs Earnings: Insufficient data to compare Paul's compensation with company performance.

CEO

Paul Josephs (60 yo)

1.8yrs
Tenure
US$1,115,305
Compensation

Mr. Paul Josephs is President, CEO & Director of Lifecore Biomedical, Inc. from May 20, 2024. Mr. Josephs is President & CEO of Woodstock Sterile Solutions, Inc. Mr. Josephs served as Senior Vice President...

Leadership Team

NamePositionTenureCompensationOwnership
Paul Josephs
President1.8yrsUS$1.12m0.62%
$ 1.7m
Ryan Lake
Executive VP & CFO1.4yrsUS$4.30m0.20%
$ 525.3k
Thomas Salus
Chief Legal & Administration Officer and Corporate Secretaryless than a yearUS$4.10m0.069%
$ 183.9k
Thomas Guldager
Senior Vice President of Operationsno datano datano data
Aaron Perlitsh
Director of Internal Audit & Chief Compliance Officerno datano datano data
Jackie Klecker
Executive Vice President of Quality & Development Services4.1yrsno datano data
Mark DaFonseca
Chief Commercial Officerless than a yearno datano data
Parker Javid
Vice Presidentno dataUS$460.69kno data
1.4yrs
Average Tenure
56yo
Average Age

Experienced Management: LFCR's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Paul Josephs
President1.8yrsUS$1.12m0.62%
$ 1.7m
Nelson Obus
Independent Director7.3yrsUS$215.00kno data
Katrina Houde
Independent Chairman of the Board6.5yrsUS$305.11k0.24%
$ 636.5k
Joshua Schechter
Independent Director5.3yrsUS$243.37k0.24%
$ 634.9k
Humberto Antunes
Independent Director1.5yrsUS$203.91k0.074%
$ 195.1k
Christopher Kiper
Independent Director3.1yrsUS$205.58kno data
Paul Johnson
Independent Director1.5yrsUS$206.12k0.066%
$ 173.9k
Jason Aryeh
Independent Director1.5yrsUS$185.48k0.066%
$ 173.9k
Matthew Korenberg
Independent Director1.5yrsUS$188.57k0.066%
$ 173.9k
1.8yrs
Average Tenure
60yo
Average Age

Experienced Board: LFCR's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/15 21:01
End of Day Share Price 2026/02/13 00:00
Earnings2025/05/25
Annual Earnings2025/05/25

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lifecore Biomedical, Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PetuskyBarrington Research Associates, Inc.
Matthew HewittCraig-Hallum Capital Group LLC
Brian HollandD.A. Davidson & Co.